June 7, 2024

 

VIA EDGAR AND FACSIMILE

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F. Street, N.E.

Washington, D.C. 20549

Attention: Tamika Sheppard

 

Re:

Lexaria Bioscience Corp. (the “Company”)

Registration Statement on Form S-1

File No. 333-279909

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Tuesday, June 11, 2024, or as soon thereafter as is practicable.

 

If you have any questions, please call Avital Perlman at 212-930-9700.

 

 

Very truly yours,

 

 

 

 

 

LEXARIA BIOSCIENCE CORP.

 

 

 

 

 

By:

/s/ Christopher Bunka

 

 

Name:

Christopher Bunka

 

 

Title:

Chief Executive Officer